Proton therapy with chemo and immunotherapy for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment for esophageal cancer that has not spread too far. It combines proton beam radiation (a precise type of radiation) with chemotherapy and immunotherapy (drugs that help your immune system fight cancer). The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with squamous cell carcinoma of the esophagus (the most common type).
- Your cancer is stage II to IVA (meaning it has not spread to distant organs).
- You are unable or unwilling to have surgery to remove the cancer.
- You have not received any previous cancer treatment.
- Your doctor expects you to live for more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
This trial looks at how best to add an immunotherapy “extra” before, during, and after standard chemoradiation for stage II–III esophageal squamous cell cancer that can’t be operated on. It may help reduce cancer that remains after treatment by targeting immune cells.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests whether adding radiation therapy to a standard treatment (immunotherapy plus chemotherapy) can help people with advanced esophageal cancer that has spread to up to two organs. The goal is to see if the combination improves outcomes.
This trial compares two standard treatments for esophageal cancer that has responded to initial chemo-immunotherapy: surgery to remove the tumor or radiation combined with chemotherapy. The goal is to see which approach offers better outcomes and quality of life.
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.